$IDYA News

IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma

IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup

Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate

Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma

IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline

RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers

Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Biosciences Plans To Commence $300M Common Stock Offering

Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

IDEAYA Biosciences And Servier Presented Complete Data From Primary Analysis Of Phase 2/3 OptimUM-02 Trial For Negative Metastatic Uveal Melanoma At ASCO Annual Meeting

IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50

IDEAYA Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Q1 EPS $(1.11) Misses $(0.98) Estimate, Sales $6.560M Beat $5.008M Estimate